Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
H. Tsubouchi (Miyazaki, Japan), A. Miura (Miyazaki, Japan), S. Yanagi (Miyazaki, Japan), M. Nakazato (Miyazaki, Japan). Ghrelin does not influence cancer progression in a lung cancer cell line and mice with lung adenocarcinoma. 2843

Member's Comments

No comment yet.

Related content which might interest you: Aerosoltherapy in lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Venothromboembolism in lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 601s Year: 2007 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Lung cancer Source: Respipedia Article Year: 2018 A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 Nonsmall cell lung cancer Source: Annual Congress 2012 - Maurizio Vignola Award for Innovation in Pneumology Ceremony (supported by Chiesi Foundation) followed by Clinical Year in Review I Year: 2012 Does the lung function affect the survival time in patients with resected non-small cell lung cancer? Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery Year: 2007 New treatment options for nonsmall cell lung cancer and small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006 Epigenetics and lung cancer Source: Annual Congress 2006 - Epigenetics and respiratory disease Year: 2006 Small cell lung cancer in patients with elderly Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 The impact of neuroendocrine differentiation in the prognosis of non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Non-small cell lung cancer with single brain metastasis: the role of surgical treatment Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer? Source: Eur Respir J 2001; 18: Suppl. 33, 232s Year: 2001 Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Deguelin enhances chemosensitivity of non-small cell lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006